申请人:Hoffman-La Roche Inc.
公开号:US06599901B1
公开(公告)日:2003-07-29
The present invention relates to compounds of the formula
wherein R is as defined herewithin. The compounds of formula I have a good affinity to the A2A receptor and therefore they may be used in the control or prevention of illnesses based on the modulation of the adenosine system, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, drug addiction, such as amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids, or against asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse. Furthermore, compounds of the present invention may be useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, aniticonvulsants and cardiaprotective agents for disorders such as coronary artery disease and heart failure.
本发明涉及下式化合物,其中R如下所定义。式I的化合物具有良好的与A2A受体的亲和力,因此它们可以用于控制或预防基于
腺苷系统调节的疾病,如阿尔茨海默病、帕
金森病、亨廷顿病、神经保护、精神分裂症、焦虑、疼痛、呼吸障碍、抑郁症、药物成瘾(如
安非他命、
可卡因、阿片类、
乙醇、
尼古丁、
大麻素)以及哮喘、过敏反应、低氧、缺血、癫痫和物质滥用等疾病。此外,本发明的化合物可以用作镇静剂、肌肉松弛剂、
抗精神病药、抗癫痫药、抗惊厥药和心脏保护剂,用于治疗冠状动脉疾病和心力衰竭等疾病。